Emmanuelle Trombe, Anthony Paronneau and Christine Wahr represented Poxel SA, a biopharmaceutical developer of innovative treatments for metabolic disorders, in its strategic partnership with Sumitomo Dainippon Pharma for the development and commercialization in Asia of diabetes treatment drug Imeglimin.